Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS

Bone Marrow Transplantation

Volumn 47, Issue 2, 2012, Pages 203-211

  Luger, S M ^a   Ringden O ^b   Zhang, M J ^c   Perez W S ^c   Bishop, M R ^d   Bornhauser, M ^e   Bredeson, C N ^f   Cairo, M S ^g   Copelan, E A ^h   Gale, R P ⁱ   Giralt, S A ^j   Gulbas, Z ^k   Gupta, V ^l   Hale, G A ^m   Lazarus, H M ⁿ   Lewis, V A ^o   Lill, M C ^p   McCarthy, P L ^q   Weisdorf, D J ^r   Pulsipher, M A ^s  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

^g NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^h TAUSSIG CANCER INSTITUTE   (United States)

ⁱ CELGENE CORPORATION   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k GAZI UNIVERSITY   (Turkey)

^l PRINCESS MARGARET HOSPITAL   (Canada)

^m JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

ⁿ UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^o ALBERTA CHILDREN'S HOSPITAL   (Canada)

^p CEDARS SINAI MEDICAL CENTER   (United States)

^q ROSWELL PARK CANCER INSTITUTE   (United States)

^r UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^s UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

more..

Author keywords

allogeneic transplant; AML; reduced intensity

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOTRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; RISK FACTOR; SURVIVAL TIME; UNRELATED DONORS; WHOLE BODY RADIATION;

EID: 84857030601     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.69     Document Type: Article

References (26)

1. Vicente D, Lamparelli T, Gualandi F, Occhini D, Raiola AM, Ibatici A et al. Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. Bone Marrow Transplant 2007; 40: 349-354. (Pubitemid 47207746)
2. Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood 1992; 79: 2578-2582.
3. Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007; 110: 1379-1387. (Pubitemid 47281440)
4. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763. (Pubitemid 28078275)
5. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
6. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536. (Pubitemid 27260263)
7. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824. (Pubitemid 28363047)
8. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444-453. (Pubitemid 46630463)
9. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A. EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplant 2006; 37: 1069-1085. (Pubitemid 43871516)
10. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003; 21: 1480-1484. (Pubitemid 46594099)
11. Martino R, Caballero MD, Perez-Simon JA, Canals C, Solano C, Urbano-Ispizua A et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100: 2243-2245. (Pubitemid 35001262)
12. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387-9393.
13. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102: 470-476. (Pubitemid 36841962)
14. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hemato-logical diseases. Blood 2003; 101: 1620-1629. (Pubitemid 36182543)
15. Flynn CM, Hirsch B, Defor T, Barker JN, Miller JS, Wagner JE et al. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol 2007; 82: 867-872. (Pubitemid 47505207)
16. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20: 128-135.
17. Massenkeil G, Nagy M, Neuburger S, Tamm I, Lutz C, le Coutre P et al. Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transplant 2005; 36: 683-689. (Pubitemid 41518710)
18. Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006; 12: 1047-1055. (Pubitemid 44603937)
19. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367-369.
20. Giralt S, Logan B, Rizzo D, Zhang MJ, Ballen K, Emmanoui-lides C et al. Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biol Blood Marrow Transplant 2007; 13: 844-852. (Pubitemid 46902440)
21. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706. (Pubitemid 29126745)
22. Klein J, Moeschberger M. Survival Analysis: Techniques of Censored and Truncated Data. 2nd edn Springer-Verlag: New York, NY, 2003.
23. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304-2312. (Pubitemid 41748028)
24. Ringden O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27: 4570-4577.
25. Report from the International Bone Marrow Transplant Registry. Advisory committee of the international bone marrow transplant registry. Bone Marrow Transplant 1989; 4: 221-228.
26. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hemato-poietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836-846. (Pubitemid 44154615)